Deucravacitinib, a selective, allosteric tyrosine kinase 2 inhibitor, in scalp psoriasis: a subset analysis of two phase 3 randomized trials in plaque psoriasis

Published: 12 December 2023| Version 1 | DOI: 10.17632/485rv9kczt.1
Contributor:
Andrew Blauvelt

Description

Plain Language Summary for Original Article titled "Deucravacitinib, a selective, allosteric tyrosine kinase 2 inhibitor, in scalp psoriasis: a subset analysis of two phase 3 randomized trials in plaque psoriasis".

Files

Categories

Clinical Trial, Scalp, Psoriasis

Funding

Bristol Myers Squibb

Licence